Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis

Shuo Yang, Yibing Hou, Xiaohui Wang, Shuo Kang, Zhenhua Pan · 2026

Read Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis by Shuo Yang, Yibing Hou, Xiaohui Wang, Shuo Kang, Zhenhua Pan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351029.txt.

Description

Shuo Yang and colleagues weighed cost against health gain for a three drug mix in advanced cervical cancer in China. The mix adds two targeted drugs to standard chemotherapy. Using trial survival data, they built a model that follows patients in three week steps over ten years and counts costs, years lived, and quality adjusted years.

The mix added about half a quality adjusted year, but at a very high extra cost. Cost per added quality year came to many times what China counts as good value. Extra checks on uncertain inputs did not change the verdict. From a public payer view, the authors conclude the mix does not give value for money at current prices.

Catalog record

CREATORShuo Yang, Yibing Hou, Xiaohui Wang, Shuo Kang, Zhenhua Pan
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE20848
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0351029

Browse the full library · About the Tower of Babel